Diabetes is the leading cause of end-stage renal disease worldwide, and 40 to 50 percent of people on dialysis in the United States have diabetes. Managing diabetes on dialysis differs fundamentally from outpatient diabetes care: A1C is unreliable, insulin needs drop sharply, dialysate composition affects glucose dynamics, and dietary rules (potassium, phosphorus, fluid) often override typical diabetes guidance. Many oral agents are contraindicated, glycated albumin and CGM replace A1C as the practical monitoring tools, and team-based care is essential.
Why Diabetes and Dialysis Overlap
Diabetic kidney disease develops over decades from glomerular damage related to hyperglycemia, hypertension, and genetic susceptibility. Microalbuminuria progresses to macroalbuminuria, eGFR falls, and end-stage renal disease eventually follows. About 40 percent of people with type 2 diabetes will develop some degree of kidney disease; about 5 percent reach ESRD. Type 1 diabetes once dominated diabetic ESRD; today type 2 supplies most cases because of its higher prevalence and earlier age of onset.
Two main forms of dialysis are used: hemodialysis (HD), typically three sessions a week at a center; and peritoneal dialysis (PD), done by the patient at home using the peritoneum as a membrane. Each has its own implications for diabetes management.
Glycemic Monitoring in ESRD
| Marker | Reliability in Dialysis | Notes |
|---|---|---|
| A1C | Reduced — often falsely low | Short RBC lifespan, EPO use, transfusions |
| Glycated albumin (GA) | Higher | Reflects 2 to 3 weeks; less affected by anemia |
| Fructosamine | Higher | Similar window; affected by hypoalbuminemia |
| Continuous glucose monitoring | Very useful | Real-time data; captures dialysis-related swings |
| Self-monitored blood glucose | Useful | Standard cornerstone |
Why A1C Falls Short on Dialysis
- Shortened RBC lifespan reduces time for glycation
- Erythropoietin stimulating agents produce younger RBCs
- Blood loss during HD or for labs reduces RBC mass
- Iron supplementation may further increase RBC turnover
- Acidemia and uremia alter hemoglobin glycation rate
- Net effect: A1C typically reads 0.5 to 1.5 percentage points lower than actual glycemic burden
Hemodialysis and Glucose Dynamics
- Glucose-free dialysate causes glucose loss during HD — hypoglycemia common in last hour
- Glucose-containing dialysate (100 to 200 mg/dL) reduces hypoglycemia risk
- Insulin needs typically drop during the dialysis day
- Heparin may slightly affect glucose metabolism
- Many patients eat during HD — meal-time insulin coverage needs adjustment
- Post-HD weight loss and volume shifts complicate insulin pharmacokinetics
Peritoneal Dialysis and Glucose Load
- Glucose-based dialysate delivers 300 to 800 grams of glucose per day systemically
- Insulin needs rise to cover continuous glucose absorption
- Higher dwell volumes and longer dwell times increase glucose load
- Icodextrin solutions reduce glucose burden but interfere with some glucose meter strips (falsely high readings)
- Weight gain and dyslipidemia more common with chronic PD
- Insulin can be added to dialysate (intraperitoneal insulin) in some programs
Insulin Adjustments Starting Dialysis
| Stage | Typical Insulin Change |
|---|---|
| Pre-dialysis, declining eGFR | Reduce 10 to 25 percent as eGFR falls below 45 |
| Initiation of HD | Reduce another 25 to 50 percent |
| Stable maintenance HD | Daily dose often less than half pre-dialysis |
| Stable PD | May be higher than pre-dialysis because of glucose load |
| Acute illness | Highly variable; close monitoring |
Non-Insulin Diabetes Medications on Dialysis
| Drug or Class | Use on Dialysis | Notes |
|---|---|---|
| Metformin | Contraindicated | Lactic acidosis risk; eGFR less than 30 cutoff |
| Glipizide | Can be used cautiously | Short-acting; preferred SU on dialysis |
| Glyburide | Avoid | Active metabolites accumulate; hypoglycemia risk |
| DPP-4 inhibitors | Use with dose reduction | Linagliptin requires no adjustment |
| GLP-1 receptor agonists | Generally safe | Liraglutide, dulaglutide, semaglutide can be used; watch GI tolerance |
| SGLT2 inhibitors | Limited use | Lose glycemic effect when eGFR very low; cardiorenal benefit lost on dialysis |
| Pioglitazone | Caution | Fluid retention worsens with dialysis |
| Acarbose | Avoid | Limited data; GI side effects |
| Repaglinide / nateglinide | Can be used | Short-acting; meal-time use |
Cardiovascular Risk
- About 40 percent annual mortality on diabetic dialysis
- Cardiovascular disease accounts for most deaths
- Standard CV risk reduction: statins (modest benefit on dialysis), aspirin in selected, BP control
- Hyperkalemia limits ACE inhibitor or ARB use sometimes
- Atrial fibrillation common; anticoagulation decisions complex
- Sudden cardiac death higher than non-diabetic dialysis
Diet on Diabetic Dialysis
| Nutrient | Typical Recommendation | Reasoning |
|---|---|---|
| Potassium | 2 to 3 grams/day | Hyperkalemia risk in ESRD |
| Phosphorus | 800 to 1,000 mg/day | Bone-mineral disease, vascular calcification |
| Sodium | 2 to 3 grams/day | Volume and BP control |
| Fluid | Often less than 1 liter/day plus urine output | Inter-dialytic weight gain control |
| Protein (HD) | 1.0 to 1.2 g/kg/day | Higher than CKD to offset dialysis losses |
| Carbohydrate | Individualized | Standard diabetic guidance overlays |
These restrictions frequently override typical diabetes nutrition advice. For example, beans, tomatoes, bananas, and some whole grains common in diabetes diets may be restricted because of potassium or phosphorus. Renal dietitians provide tailored guidance.
Hypoglycemia Risks
- Reduced insulin clearance
- Improved insulin sensitivity with each dialysis session
- Anorexia and reduced food intake
- Autonomic neuropathy blunts hypoglycemia awareness
- Beta-blockers, ACE inhibitors mask warning signs
- Glucose-free dialysate during HD
- Polypharmacy
Transplantation
- Kidney transplant offers better survival and quality of life than dialysis
- Simultaneous pancreas-kidney (SPK) transplant for type 1 — improves both insulin independence and renal function
- Pancreas after kidney (PAK) — for type 1 already on a kidney
- Pancreas alone — rarely chosen because of immunosuppression risks
- Type 2 with low BMI may also be considered for SPK in select programs
- Wait times vary; transplant requires careful glycemic control during workup
Foot Care on Dialysis
- Diabetic foot ulcers extremely common in this population
- Amputation rates many times higher than non-dialysis diabetes
- Vascular calcification and small vessel disease combine
- Daily inspection, podiatry care, off-loading, and prompt ulcer treatment essential
- See our guide on diabetic foot ulcer staging
Practical Tips
- Get baseline glycated albumin or use CGM
- Carry hypoglycemia treatment to and from dialysis
- Test fingerstick before and after each HD session
- Adjust meals around HD timing
- Track dry weight changes alongside insulin needs
- Coordinate appointments — nephrology and endocrinology often share notes
- Address depression, common in dialysis populations
- For wider context, see our complications and related conditions hub
The Bottom Line
Diabetes and dialysis overlap in 40 to 50 percent of U.S. dialysis patients, and managing diabetes on dialysis differs sharply from outpatient care. A1C is unreliable; glycated albumin, fructosamine, and CGM are preferred. Insulin needs typically fall 25 to 50 percent on starting hemodialysis but may rise on peritoneal dialysis because of glucose-containing dialysate. Metformin is contraindicated; glipizide, DPP-4 inhibitors, and GLP-1 receptor agonists can be used with attention to dose. Diet rules from ESRD often override typical diabetes nutrition. Hypoglycemia, cardiovascular disease, and foot ulcers are major risks. Transplantation, including simultaneous pancreas-kidney transplant in select type 1 patients, offers the best long-term outlook. Talk to your nephrology and diabetes team about an individualized plan, and seek emergency care for chest pain, sudden vision change, or unresponsive low blood sugar.
